Business Wire03.27.18
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc. (LMI), has appointed Gary J. Pruden, Kenneth J. Pucel and Dr. James H. Thrall as members of its Board of Directors. The company’s board now consists of 10 members.
Pruden, who will serve as a member of the Audit Committee and the Financing and Strategy Committee, has over 30 years of experience in the global healthcare industry. Pruden held a number of senior commercial leadership positions across both the medical device and pharmaceutical sectors of Johnson & Johnson from 1985 until 2017, including executive vice president, Worldwide Chairman, Medical Devices.
Pucel, who will serve as a member of the Compensation Committee, has been executive vice president of Global Operations, Engineering & Lean, at Polaris Industries Inc. since Dec. 1, 2014. Previously, Pucel was with Boston Scientific Corporation, a global provider of medical solutions, where he held positions of increasing responsibility, most recently as executive vice president of Global Operations, Quality and Technology from 2012 through 2014, and as a member of BSC’s Executive Committee from 2004 through 2014.
Thrall, who will serve as a member of the Nominating and Corporate Governance Committee, currently holds the Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as chairman of the Department of Radiology at Massachusetts General Hospital from 1988 until 2013. Thrall is also a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies.
“We welcome Gary, Ken and Jim to the Board,” said Mary Anne Heino, Lantheus president and CEO. “Each of our new directors will, in his own individual way, be able to contribute significantly to our corporate growth strategy. Gary brings to us global pharmaceutical experience, including in the strategy, operations, business development and regulatory areas, making him uniquely suited to this growth phase of our company. Ken’s expertise in manufacturing, supply chain and distribution will prove invaluable as we build out additional specialized manufacturing capabilities and expand our product offerings. Jim’s intimate knowledge of nuclear medicine, radiology and clinical practice will further strengthen our ability to lead the next generation of diagnostic imaging. With these new directors, our company’s capabilities are stronger than ever.”
Lantheus Holdings Inc. is the parent company of Lantheus Medical Imaging Inc., a global developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a portfolio of products, including the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The company is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.
Pruden, who will serve as a member of the Audit Committee and the Financing and Strategy Committee, has over 30 years of experience in the global healthcare industry. Pruden held a number of senior commercial leadership positions across both the medical device and pharmaceutical sectors of Johnson & Johnson from 1985 until 2017, including executive vice president, Worldwide Chairman, Medical Devices.
Pucel, who will serve as a member of the Compensation Committee, has been executive vice president of Global Operations, Engineering & Lean, at Polaris Industries Inc. since Dec. 1, 2014. Previously, Pucel was with Boston Scientific Corporation, a global provider of medical solutions, where he held positions of increasing responsibility, most recently as executive vice president of Global Operations, Quality and Technology from 2012 through 2014, and as a member of BSC’s Executive Committee from 2004 through 2014.
Thrall, who will serve as a member of the Nominating and Corporate Governance Committee, currently holds the Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as chairman of the Department of Radiology at Massachusetts General Hospital from 1988 until 2013. Thrall is also a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies.
“We welcome Gary, Ken and Jim to the Board,” said Mary Anne Heino, Lantheus president and CEO. “Each of our new directors will, in his own individual way, be able to contribute significantly to our corporate growth strategy. Gary brings to us global pharmaceutical experience, including in the strategy, operations, business development and regulatory areas, making him uniquely suited to this growth phase of our company. Ken’s expertise in manufacturing, supply chain and distribution will prove invaluable as we build out additional specialized manufacturing capabilities and expand our product offerings. Jim’s intimate knowledge of nuclear medicine, radiology and clinical practice will further strengthen our ability to lead the next generation of diagnostic imaging. With these new directors, our company’s capabilities are stronger than ever.”
Lantheus Holdings Inc. is the parent company of Lantheus Medical Imaging Inc., a global developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a portfolio of products, including the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The company is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.
